Format

Send to

Choose Destination
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):5012-9. doi: 10.1167/iovs.15-17142.

Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma.

Author information

1
Visual Research Project Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan 2Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.
2
Visual Research Project Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
3
Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.

Abstract

PURPOSE:

To assess the therapeutic potential of spermidine in mice with excitatory amino acid carrier 1 (EAAC1) deletion (EAAC1 knockout [KO] mice), a mouse model of normal tension glaucoma.

METHODS:

Spermidine, at 30 mM in drinking water, was administered to EAAC1 KO mice from 5 to 12 weeks old. Optical coherence tomography, multifocal electroretinograms, and the measurement of intraocular pressure (IOP) were performed at 5, 8, and 12 weeks old. Histopathology analyses were carried out at 8 and 12 weeks old, and immunoblot and immunohistochemical analyses of 4-hydroxy-2-nonenal (4-HNE) in the retina were performed at 8 weeks old.

RESULTS:

Spermidine ameliorated retinal degeneration and improved visual function in EAAC1 KO mice at both 8 and 12 weeks old, without affecting IOP. A significant increase of 4-HNE was observed in vehicle-treated EAAC1 KO mice, but spermidine treatment reduced this increase, suggesting that spermidine alleviated the severity of the glaucoma-like phenotype by acting as an antioxidant.

CONCLUSIONS:

The results from this study suggest that oral spermidine administration could be a useful treatment for retinal degenerative disorders including glaucoma.

PMID:
26230766
DOI:
10.1167/iovs.15-17142
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center